Treatment effects on neurometabolite levels in schizophrenia: A meta-analysis dataset of proton magnetic resonance spectroscopy
This article describes a dataset for a meta-analysis that aimed to investigate the effects of treatment on the neurometabolite status in patients with schizophrenia (DOI of original article: https://doi.org/10.1016/j.schres.2020.03.069 [1]). The data search was performed with MEDLINE, Embase, and Ps...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-08-01
|
Series: | Data in Brief |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352340920307563 |
id |
doaj-ca47ab69a7014fcca0726c83de4d510e |
---|---|
record_format |
Article |
spelling |
doaj-ca47ab69a7014fcca0726c83de4d510e2020-11-25T01:58:55ZengElsevierData in Brief2352-34092020-08-0131105862Treatment effects on neurometabolite levels in schizophrenia: A meta-analysis dataset of proton magnetic resonance spectroscopyManabu Kubota0Sho Moriguchi1Keisuke Takahata2Shinichiro Nakajima3Nobuyuki Horita4Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan; Department of Psychiatry, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan; Corresponding author at: Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology; and Department of Psychiatry, Kyoto University Graduate School of Medicine, Address: 4-9-1 Anagawa, Inage-ku, Chiba, Chiba 263-8555, Japan.Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, 250 College Street, Toronto, Ontario M5T1R8, CanadaDepartment of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan; Department of Neuropsychiatry, Keio University Graduate School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanResearch Imaging Centre, Centre for Addiction and Mental Health, Toronto, 250 College Street, Toronto, Ontario M5T1R8, Canada; Department of Neuropsychiatry, Keio University Graduate School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanYokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, JapanThis article describes a dataset for a meta-analysis that aimed to investigate the effects of treatment on the neurometabolite status in patients with schizophrenia (DOI of original article: https://doi.org/10.1016/j.schres.2020.03.069 [1]). The data search was performed with MEDLINE, Embase, and PsycINFO. The neurometabolites investigated include glutamate, glutamine, glutamate + glutamine, gamma-aminobutyric acid, N-acetylaspartate, and myo-inositol, and the regions of interest (ROIs) include the frontal cortex, temporal cortex, parieto-occipital cortex, thalamus, basal ganglia, and hippocampus. The meta-analysis was conducted with a random-effects model, and the use of the standardized mean difference method between pre- and post-treatment of subjects for neurometabolites in each ROI of three patient groups or more. The dataset covers raw data of 39 patient groups (773 patients with schizophrenia at follow-up) with neurometabolite levels measured by magnetic resonance spectroscopy both before and after treatment. Furthermore, it contains details of clinical characteristics and treatment types for each group. Therefore, the data would be useful for a reinvestigation of treatment effects on the neurometabolite status from diverse points of view, as well as for the development of future treatment strategies for psychiatric diseases.http://www.sciencedirect.com/science/article/pii/S2352340920307563MRSGlutamateGlutamineGamma-aminobutyric acidN-acetylaspartateMyo-inositol |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Manabu Kubota Sho Moriguchi Keisuke Takahata Shinichiro Nakajima Nobuyuki Horita |
spellingShingle |
Manabu Kubota Sho Moriguchi Keisuke Takahata Shinichiro Nakajima Nobuyuki Horita Treatment effects on neurometabolite levels in schizophrenia: A meta-analysis dataset of proton magnetic resonance spectroscopy Data in Brief MRS Glutamate Glutamine Gamma-aminobutyric acid N-acetylaspartate Myo-inositol |
author_facet |
Manabu Kubota Sho Moriguchi Keisuke Takahata Shinichiro Nakajima Nobuyuki Horita |
author_sort |
Manabu Kubota |
title |
Treatment effects on neurometabolite levels in schizophrenia: A meta-analysis dataset of proton magnetic resonance spectroscopy |
title_short |
Treatment effects on neurometabolite levels in schizophrenia: A meta-analysis dataset of proton magnetic resonance spectroscopy |
title_full |
Treatment effects on neurometabolite levels in schizophrenia: A meta-analysis dataset of proton magnetic resonance spectroscopy |
title_fullStr |
Treatment effects on neurometabolite levels in schizophrenia: A meta-analysis dataset of proton magnetic resonance spectroscopy |
title_full_unstemmed |
Treatment effects on neurometabolite levels in schizophrenia: A meta-analysis dataset of proton magnetic resonance spectroscopy |
title_sort |
treatment effects on neurometabolite levels in schizophrenia: a meta-analysis dataset of proton magnetic resonance spectroscopy |
publisher |
Elsevier |
series |
Data in Brief |
issn |
2352-3409 |
publishDate |
2020-08-01 |
description |
This article describes a dataset for a meta-analysis that aimed to investigate the effects of treatment on the neurometabolite status in patients with schizophrenia (DOI of original article: https://doi.org/10.1016/j.schres.2020.03.069 [1]). The data search was performed with MEDLINE, Embase, and PsycINFO. The neurometabolites investigated include glutamate, glutamine, glutamate + glutamine, gamma-aminobutyric acid, N-acetylaspartate, and myo-inositol, and the regions of interest (ROIs) include the frontal cortex, temporal cortex, parieto-occipital cortex, thalamus, basal ganglia, and hippocampus. The meta-analysis was conducted with a random-effects model, and the use of the standardized mean difference method between pre- and post-treatment of subjects for neurometabolites in each ROI of three patient groups or more. The dataset covers raw data of 39 patient groups (773 patients with schizophrenia at follow-up) with neurometabolite levels measured by magnetic resonance spectroscopy both before and after treatment. Furthermore, it contains details of clinical characteristics and treatment types for each group. Therefore, the data would be useful for a reinvestigation of treatment effects on the neurometabolite status from diverse points of view, as well as for the development of future treatment strategies for psychiatric diseases. |
topic |
MRS Glutamate Glutamine Gamma-aminobutyric acid N-acetylaspartate Myo-inositol |
url |
http://www.sciencedirect.com/science/article/pii/S2352340920307563 |
work_keys_str_mv |
AT manabukubota treatmenteffectsonneurometabolitelevelsinschizophreniaametaanalysisdatasetofprotonmagneticresonancespectroscopy AT shomoriguchi treatmenteffectsonneurometabolitelevelsinschizophreniaametaanalysisdatasetofprotonmagneticresonancespectroscopy AT keisuketakahata treatmenteffectsonneurometabolitelevelsinschizophreniaametaanalysisdatasetofprotonmagneticresonancespectroscopy AT shinichironakajima treatmenteffectsonneurometabolitelevelsinschizophreniaametaanalysisdatasetofprotonmagneticresonancespectroscopy AT nobuyukihorita treatmenteffectsonneurometabolitelevelsinschizophreniaametaanalysisdatasetofprotonmagneticresonancespectroscopy |
_version_ |
1724967149943914496 |